{"id":"NCT04109066","sponsor":"Bristol-Myers Squibb","briefTitle":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","officialTitle":"A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-18","primaryCompletion":"2023-01-16","completion":"2023-12-27","firstPosted":"2019-09-30","resultsPosted":"2024-03-12","lastUpdate":"2025-01-08"},"enrollment":521,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"nivolumab","otherNames":[]},{"type":"DRUG","name":"paclitaxel (PTX)","otherNames":[]},{"type":"OTHER","name":"nivolumab placebo","otherNames":[]},{"type":"DRUG","name":"anthracycline","otherNames":[]},{"type":"DRUG","name":"cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Endocrine Therapy","otherNames":[]},{"type":"PROCEDURE","name":"Surgery","otherNames":[]}],"arms":[{"label":"Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET","type":"EXPERIMENTAL"},{"label":"Arm B: Placebo combined with neoadjuvant CT and then adjuvant ET","type":"PLACEBO_COMPARATOR"}],"summary":"A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.","primaryOutcome":{"measure":"Pathological Complete Response (pCR) Rate","timeFrame":"Up to approximately 37 months","effectByArm":[{"arm":"Arm A","deltaMin":24.5,"sd":null},{"arm":"Arm B","deltaMin":13.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0021"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":240,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Hong Kong","Ireland","Italy","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39838118","38913933"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":127},"commonTop":["Alopecia","Nausea","Anaemia","Fatigue","Diarrhoea"]}}